TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Aggressive, Noncontiguous Stage II/III/IV B-Cell Non-Hodgkin Lymphoma
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
The treatment of choice for patients with advanced stages of aggressive non-Hodgkin lymphoma (NHL) is combination chemotherapy, either alone or supplemented by local-field radiation therapy.[1]
Source links and citations
The following drug combinations are referred to in this section:
Pola-R-CHP: polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
R-CHOP: rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
R-ACVBP: rituximab, an anti–CD20 monoclonal antibody + doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice